Updated: FDA signals likely full approval for Eisai's new Alzheimer's drug ahead of Friday's adcomm
The FDA said Wednesday that the confirmatory trial that Eisai and Biogen ran to show their new Alzheimer’s drug has a clinical benefit did indeed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
